Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Temozolomide (Primary)
- Indications Astrocytoma; Glioma; Oligodendroglioma
- Focus Pharmacogenomic; Therapeutic Use
- 12 Dec 2017 Planned End Date changed from 1 May 2026 to 31 Dec 2026.
- 12 Dec 2017 Planned primary completion date changed from 1 May 2026 to 31 Dec 2021.
- 12 Dec 2017 Status changed from recruiting to active, no longer recruiting.